Orrick represented JMP Securities and Dougherty & Company as underwriters for a follow-on public offering of 2,683,334 shares of common stock by AxoGen, Inc. (“AxoGen”), including shares purchased by the underwriters pursuant to an option to purchase additional shares. The offering resulted in gross proceeds of approximately $20.1 million for AxoGen.
AxoGen (NASDAQ: AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. The net proceeds to the company from the offering are expected to be used for general working capital purposes and expanded development of nerve repair markets and products.
The Orrick team was led by Capital Markets partner Andrew Thorpe and included associates Kenneth Marx, Ajay Koduri, Stephanie Richards and Conner Pine.View the company's press release below.